A team of researchers, affiliated with UNIST has recently introduced a novel targeted drug delivery system that can improve the pharmacological and therapeutic properties of conventional cancer treatments.
A team of researchers, affiliated with UNIST has recently introduced a novel targeted drug delivery system that can improve the pharmacological and therapeutic properties of conventional cancer treatments. The new technology has dramatically enhanced safety and efficiency through the use of the supramolecularly built protein corona shield as a targeting agent through regulating the interfaces between nanoparticles and biological systems.
This breakthrough has been jointly led by Professor Ja-Hyoung Ryu, Professor Sebyung Kang, and Professor Chaekyu Kim in the School of Life Sciences at UNIST. Their findings have been published online in Nature Communications (IF: 12.353) on October 31, 2018.
Targeted drug delivery system refers to the method that selectively transports drugs to targeted tissues, organs, and cells through a variety of drugs carrier. Though tens of thousands of drug delivery systems have been developed, the effect has been minimal. This is because hundreds of proteins in the body stick to the drug delivery system (protein corona phenomenon). Because of this phenomenon, even when the drug reaches a target such as a cancer cell, the treatment efficiency is very low, and other side effects have been observed, which may cause toxic side effects.
Read more at Ulsan National Institute of Science and Technology (UNIST)
Image: From left are Professor Ja-Hyoung Ryu (School of Natural Science), Professor Chaekyu Kim (School of Natural Science), and Professor Sebyung Kang (School of Life Sciences) at UNIST. (Credit: UNIST)
